Abbott Flexnav News Today

Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation

Abbott (NYSE:ABT) announced today that it received FDA approval for its latest-generation transcatheter aortic valve implant (TAVI) system.

Abbott has announced it has received the CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk. 

Abbott  today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation system, Navitor™, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk. With the Navitor valve, the company is advancing TAVI therapies with innovations including a unique design to prevent blood leaking around the … Abbott (NYSE: ABT) today announced it has received CE Mark for its latest-gene...

May 17, 2021 11:35am The Navitor artificial heart valve is implanted using Abbott’s CE-marked FlexNav delivery device and reduces the blood leaks that often occur after replacement. (Abbott) After Boston Scientific retired its entire line of Lotus Edge replacement heart valves late last year amid a flurry of issues with its delivery system, Abbott has stepped up to fill in the gap in the transcatheter aortic valve replacement market. Abbott’s Navitor TAVR system has received a CE ma...